@entity16891 for acute treatment of XXXX -related @entity2741 . A randomized, double-blind comparison to @entity175 .

@entity1 @entity175 @entity2741 @entity706 @entity16891 @entity5 @entity18377 @entity1483 @entity413 @entity14645 @entity460 @entity1011 @entity3243 @entity4028
STUDY OBJECTIVE: To determine whether @entity16891 therapy is superior to maximally approved doses of @entity175 for acute control of @entity5 -related @entity2741 . DESIGN: Randomized, double-blind comparison of active treatments. SETTING: Comprehensive @entity5 center. @entity1 : One hundred ninety-eight consecutive hypercalcemic events in 164 @entity1 screened for entry. ELIGIBILITY CRITERIA: hospitalization and intravenous hydration for at least 2 days; persistent elevated serum @entity460 levels of 2.99 mmol/L or greater (adjusted for serum albumin); serum @entity1011 levels of 221 mumol/L or less; no cytotoxic chemotherapy, radiation, or @entity18377 within the preceding 7 days or during study; no concurrent use of @entity4028 antibiotics; life expectancy greater than 4 weeks; @entity706 and @entity3243 excluded. @entity1 were stratified by histologic type of @entity5 (epidermoid or nonepidermoid). Fifty @entity1 were randomized and treated. INTERVENTIONS: @entity16891 200 mg/m2 body surface area for 5 days by continuous intravenous infusion, or salmon @entity175 8 IU/kg body weight every 6 hours for 5 days by intramuscular injection. @entity1 randomized to receive @entity16891 received sham injections of saline to simulate @entity175 ; @entity1 randomized to receive @entity175 received 1000 mL 5%- @entity413 solution to simulate @entity16891 . MEASUREMENTS AND MAIN RESULTS: All @entity1 were evaluable. Eighteen of twenty-four @entity1 who received @entity16891 achieved normocalcemia compared with 8 of 26 @entity1 who received @entity175 for an observed difference of 44% (95% confidence interval, 19% to 69%; P = 0.002). Median duration of normocalcemia before other cytotoxic or @entity14645 therapy was 6 days for @entity1 treated with @entity16891 compared with 1 day for @entity1 treated with @entity175 (P less than 0.001). Median duration of normocalcemia regardless of intercurrent treatment and without adjustment for serum albumin was 11+ days for @entity1 treated with @entity16891 and 2 days for @entity1 treated with @entity175 (P less than 0.01). Mean daily fluid intake and mean daily dose of @entity1483 were similar in both treatment groups. No additional benefit was seen in 9 @entity1 randomized to receive @entity175 who incidentally received corticosteroids. CONCLUSIONS: @entity16891 therapy is highly effective and superior to maximally approved doses of @entity175 for acute control of @entity5 -related @entity2741 .
